Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perseus Proteomics Inc., in collaboration with Juntendo University, has successfully registered a patent in Japan for PPMX-T003, a therapeutic drug aimed at treating polycythemia vera. The company has also filed for patents internationally and is focused on fortifying their intellectual property portfolio for the various therapeutic uses of this antibody. There will be no impact from this patent registration on the financial results for the fiscal year ending March 31, 2025.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.